Adaptimmune Therapeutics Plc Working Capital to Net Assets Ratio
Adaptimmune Therapeutics Plc working capital to net assets ratio. Adaptimmune Therapeutics Plc (ADAP) has a Working Capital to Net Assets ratio of -37.5% as of June 2025. Working capital of $26.60 Million (current assets of $78.11 Million minus current liabilities of $51.51 Million) is measured against net assets of $-70.96 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible net worth ratio of Adaptimmune Therapeutics Plc to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Adaptimmune Therapeutics Plc (2011–2024)
Working capital to net assets ratio of Adaptimmune Therapeutics Plc from 2011 to 2024. This chart shows how Adaptimmune Therapeutics Plc's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2011 to 2024. As of June 2025, the ratio stands at -37.5%, reflecting working capital of $26.60 Million against net assets of $-70.96 Million USD. See ADAP defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Adaptimmune Therapeutics Plc Working Capital to Net Assets Ratio by Year (2011–2024)
Adaptimmune Therapeutics Plc working capital to net assets ratio by year from 2011 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Adaptimmune Therapeutics Plc from 2011 to 2024, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see ADAP total asset value.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 1043.5% | $123.64 Million | $11.85 Million | $188.17 Million | $64.53 Million | ▲ +702.4 pp |
| 2023 | 341.1% | $134.76 Million | $39.51 Million | $207.55 Million | $72.79 Million | ▲ +107.9 pp |
| 2022 | 233.1% | $190.87 Million | $81.88 Million | $255.37 Million | $64.50 Million | ▲ +61.8 pp |
| 2021 | 171.4% | $352.92 Million | $205.96 Million | $415.46 Million | $62.54 Million | ▲ +66.1 pp |
| 2020 | 105.2% | $359.08 Million | $341.23 Million | $398.15 Million | $39.07 Million | ▲ +35.6 pp |
| 2019 | 69.7% | $86.15 Million | $123.64 Million | $120.49 Million | $34.34 Million | ▼ -14.0 pp |
| 2018 | 83.7% | $206.66 Million | $246.88 Million | $231.09 Million | $24.44 Million | ▲ +6.9 pp |
| 2017 | 76.8% | $155.87 Million | $202.98 Million | $230.18 Million | $74.31 Million | ▼ -18.6 pp |
| 2016 | 95.4% | $158.48 Million | $166.14 Million | $198.75 Million | $40.27 Million | ▼ -8.0 pp |
| 2015 | 103.4% | $268.35 Million | $259.61 Million | $295.11 Million | $26.76 Million | ▲ +0.0 pp |
| 2014 | 103.4% | $268.35 Million | $259.61 Million | $295.11 Million | $26.76 Million | ▲ +62.7 pp |
| 2013 | 40.6% | $979.32K | $2.41 Million | $54.09 Million | $53.11 Million | ▼ -69.0 pp |
| 2012 | 109.7% | $-2.36 Million | $-2.16 Million | $1.60 Million | $3.97 Million | ▼ -67.8 pp |
| 2011 | 177.5% | $-223.04K | $-125.66K | $3.87 Million | $4.09 Million | — |